Aegerion Pharmaceuticals Announces Lomitapide 78-Week Phase III Clinical Data Consistent With Earlier Results

Aegerion Pharmaceuticals, Inc.

, an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, today provided a clinical update on its lead investigational therapeutic, lomitapide. Aegerion reported that the 78-week data from its pivotal Phase III clinical trial are consistent with data previously reported at the 26- and 56-week time points. The Phase III study was a single-arm, open label trial, designed to evaluate the efficacy and long-term safety of lomitapide for the treatment of patients with homozygous familial hypercholesterolemia (HoFH). The data demonstrate that the reduction in LDL-C cholesterol from baseline was maintained at 78-weeks.